Last reviewed · How we verify
Eramin (HISTAMINE)
Eramin, also known as histamine, is a small molecule histamine drug originally developed by Lilly and currently owned by the same company. It targets the histamine H3 receptor and was FDA approved in 1939 for various indications including acute myeloid leukemia, hyposensitization to allergens, and osteoarthritis. Eramin is off-patent and has no active Orange Book patents, meaning it is available as a generic medication. However, there are currently no generic manufacturers of Eramin. As an off-patent medication, key safety considerations should be carefully evaluated.
At a glance
| Generic name | HISTAMINE |
|---|---|
| Sponsor | Eli Lilly |
| Drug class | histamine |
| Target | Histamine H3 receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| First approval | 1939 |
Approved indications
- Acute myeloid leukemia, disease
- Hyposensitization to allergens
- Osteoarthritis
Common side effects
- Flushing
- Dizziness
- Headache
- Urticaria
- Vomiting
- Metallic taste
- Abdominal cramps
Serious adverse events
- Anaphylactic reaction
- Bronchial constriction
- Asthma
- Marked hypotension
- Marked hypertension
- Generalized allergic manifestations
- Systemic reactions
- Vasomotor collapse
- Profound shock
Key clinical trials
- A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS) (PHASE3)
- Effect of Low Histamine-Based Modified Mediterranean Diet in Multiple Sclerosis (NA)
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) (PHASE3)
- Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection
- Antihistamines, Amantadine and Evolution of the SARS-CoV-2 Infection
- A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) (PHASE1,PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Eramin CI brief — competitive landscape report
- Eramin updates RSS · CI watch RSS
- Eli Lilly portfolio CI